This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
zacks-rank: Archive
Drilling Tools International Corp. (DTI) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Drilling Tools International Corp. (DTI) delivered earnings and revenue surprises of +300.00% and +9.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
DTINegative Net Change ACDCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Fidelity National Financial (FNF) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Fidelity National Financial (FNF) delivered earnings and revenue surprises of +13.99% and +13.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
FNFNegative Net Change BMOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
HireQuest, Inc. (HQI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
HireQuest (HQI) delivered earnings and revenue surprises of +71.43% and +11.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
HQINegative Net Change CXMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
IREN Limited (IREN) Reports Q1 Loss, Beats Revenue Estimates
by Zacks Equity Research
IREN Limited (IREN) delivered earnings and revenue surprises of -342.86% and +8.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
IRENNegative Net Change INTRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ABCLNegative Net Change CLSDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
AerSale Corporation (ASLE) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AerSale (ASLE) delivered earnings and revenue surprises of -60.00% and -16.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ASLENegative Net Change AVAVNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
DiamondRock Hospitality (DRH) Surpasses Q3 FFO and Revenue Estimates
by Zacks Equity Research
DiamondRock Hospitality (DRH) delivered FFO and revenue surprises of +16.00% and +0.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
DRHPositive Net Change GBDCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sweetgreen, Inc. (SG) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sweetgreen (SG) delivered earnings and revenue surprises of -50.00% and -4.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
SGNegative Net Change FATNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
The Beauty Health Company (SKIN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of -12.50% and +2.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
SKINNegative Net Change SNDAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Treace Medical Concepts (TMCI) Reports Q3 Loss, Beats Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of +7.14% and +1.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
TMCINegative Net Change SIBNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates
by Zacks Equity Research
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of +3.33% and +16.60%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
LFCRNegative Net Change BFRIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
MP Materials Corp. (MP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MP Materials (MP) delivered earnings and revenue surprises of +28.57% and +0.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
MPNegative Net Change SGMLNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Onto Innovation (ONTO) Tops Q3 Earnings Estimates
by Zacks Equity Research
Onto Innovation (ONTO) delivered earnings and revenue surprises of +5.75% and -0.02%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ONTONegative Net Change DFLINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
PAR Technology (PAR) Misses Q3 Earnings Estimates
by Zacks Equity Research
PAR Technology (PAR) delivered earnings and revenue surprises of -33.33% and +8.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
PARNegative Net Change RPAYNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Figs (FIGS) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Figs (FIGS) delivered earnings and revenue surprises of +150.00% and +6.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
FIGSNegative Net Change ONONNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Huntsman (HUN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Huntsman (HUN) delivered earnings and revenue surprises of +76.92% and +1.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
HUNNegative Net Change NTICNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Universal Logistics (ULH) Beats Q3 Earnings Estimates
by Zacks Equity Research
Universal Truckload (ULH) delivered earnings and revenue surprises of +33.33% and -0.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ULHNegative Net Change PALNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of +13.33% and -2.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ZYMENegative Net Change IRDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -153.85% and +9.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ETONNegative Net Change AYTUNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Five9 (FIVN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Five9 (FIVN) delivered earnings and revenue surprises of +6.85% and +0.46%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
FIVNNegative Net Change CLBTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Microchip Technology (MCHP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Microchip Tech (MCHP) delivered earnings and revenue surprises of +6.06% and +0.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
MCHPNegative Net Change ADINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
BioLife Solutions, Inc. (BLFS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +500.00% and +8.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BLFSNegative Net Change APositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
EOG Resources (EOG) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
EOG Resources (EOG) delivered earnings and revenue surprises of +11.52% and -1.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
EOGNegative Net Change EPMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 0.00% and +4.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
TNDMNegative Net Change SINTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
VTEX (VTEX) Meets Q3 Earnings Estimates
by Zacks Equity Research
VTEX (VTEX) delivered earnings and revenue surprises of 0.00% and -0.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
VTEXNegative Net Change SNOWNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank